American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

10.1200/JCO.1997.15.8.2996

Smith TJ, Somerfield MR: The ASCO experience with evidence-based clinical practice guidelines. Oncology (Huntington) 11:223,1997-227,

10.1164/ajrccm.153.1.8542152

10.1183/09031936.96.09122560

10.1007/BF01731846

10.1007/BF00843701

10.1136/thx.52.2.187

10.1136/thx.52.5.438

10.1200/JCO.1998.16.6.2142

10.1016/S0169-5002(98)00026-9

10.1016/S0003-4975(99)00788-2

10.1148/radiology.213.2.r99nv46530

10.1016/S1010-7940(99)00179-7

10.1055/s-2007-1013107

10.1148/radiology.212.3.r99se21803

10.1148/radiology.215.3.r00jn29886

10.1016/S1470-2045(01)00555-1

Hicks RJ, Kalff V, MacManus MP, et al: (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 42:1596,2001-1604,

10.1378/chest.120.2.521

10.1016/S0003-4975(01)03432-4

10.1016/S0003-4975(98)01257-0

10.1016/0003-4975(95)00752-0

10.1007/s002590050327

10.1378/chest.112.6.1480

10.1097/00000421-200002000-00014

10.1006/jsre.2002.6354

10.1016/S1010-7940(01)00827-2

10.1378/chest.117.3.773

10.1148/radiology.202.2.9015071

10.1016/S0022-5223(96)70317-3

10.1378/chest.108.6.1617

10.1056/NEJM200007273430404

10.1016/S0003-4975(00)01769-0

10.1055/s-2000-9870

10.1183/09031936.97.10071547

10.1016/S1010-7940(97)00084-5

10.1016/S1010-7940(97)00253-4

Magnani P, Carretta A, Rizzo G, et al: FDG/PET and spiral CT image fusion for medistinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 40:741,1999-748,

10.1016/S0140-6736(02)08352-6

10.1200/JCO.2001.19.1.111

Changlai SP, Tsai SC, Chou MC, et al: Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep 8:337,2001-339,

10.1016/S0167-8140(00)00138-9

10.1016/S0360-3016(01)01722-9

10.1016/S0360-3016(00)01579-0

10.1002/1097-0142(20010815)92:4<886::AID-CNCR1397>3.0.CO;2-V

10.1007/s002590000376

10.1016/S0003-4975(98)01055-8

Gambhir SS, Hoh CK, Phelps ME, et al: Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 37:1428,1996-1436,

10.1183/09031936.94.07020265

Steiner RM, Liu JB, Goldberg BB, et al: The value of ultrasound-guided fiberoptic bronchoscopy. Clin Chest Med 16:519,1995-534,

10.1378/chest.104.4.1012

10.1016/S0169-5002(01)00353-1

10.1016/S0003-4975(01)03205-2

10.1148/radiology.219.1.r01ap44252

10.1007/BF00619947

10.1016/S0003-4975(01)03447-6

10.1016/S0025-6196(11)62330-6

10.7326/0003-4819-127-8_Part_1-199710150-00004

10.1164/ajrccm.161.2.9902040

10.1055/s-1999-74

10.1378/chest.112.4_Supplement.239S

10.1016/S0003-4975(99)00983-2

10.1378/chest.111.6.1710

10.1067/mtc.2000.106089

Komaki R, Roth JA, Walsh GL, et al: Outcome predictors for 143 patients with superior sulcus tumors treated by multidisciplinary approach at the University of Texas M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 48:347,2000-354,

10.1016/S1076-6332(99)80207-4

10.1016/S0360-3016(01)01477-8

10.1067/mtc.2002.123130

10.1053/ejso.2001.1144

10.1016/S0003-4975(98)00675-4

10.1016/S0360-3016(01)02673-6

10.1200/JCO.1998.16.3.1075

10.1097/00003072-200105000-00001

10.1378/chest.112.2.416

10.2214/ajr.175.1.1750245

Schirrmeister H, Glatting G, Hetzel J, et al: Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42:1800,2001-1804,

10.1007/s002590050291

10.1148/radiology.211.1.r99ap34137

10.1200/JCO.2001.19.5.1344

10.1378/chest.115.3.714

10.1016/S1010-7940(99)00047-0

10.2214/ajr.168.5.9129444

Yun M, Kim W, Alnafisi N, et al: 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795,2001-1799,

10.1148/radiology.209.3.9844679

10.1016/S0003-4975(97)01038-2

10.2214/ajr.174.4.1741033

10.1016/S0730-725X(00)00160-0

10.2214/ajr.170.4.9530054

10.1002/1522-2586(200006)11:6<647::AID-JMRI11>3.0.CO;2-F

10.1097/00000421-200206000-00007

10.1378/chest.117.2.358

10.1016/S0360-3016(01)01666-2

10.1093/jnci/88.17.1210

10.1016/S0360-3016(97)00365-9

Curran WJ Jr, Scott C, Langer C, et al: Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC): Initial report of radiation therapy oncology group (RTOG) 9410. Proc Am Soc Clin Oncol 19:484,2000, (abstr 1891)

10.1200/JCO.1999.17.9.2692

Belani CP: Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer. Semin Oncol 26:44,1999-54,

10.1200/JCO.1998.16.6.2157

10.1634/theoncologist.6-suppl_1-25

10.1097/00001622-200103000-00005

10.1200/JCO.2002.03.054

10.1200/JCO.1999.17.1.4

10.1067/mtc.2001.112465

10.1016/S0169-5002(01)00466-4

10.1016/S0169-5002(99)00045-8

10.1093/jnci/86.9.673

10.1016/S0169-5002(98)00046-4

10.1200/jco.2002.20.1.247

10.1053/srao.2000.9128

10.1200/JCO.1999.17.10.3188

10.1016/S0169-5002(99)00017-3

10.1016/S0959-8049(97)10122-8

Stephens RJ, Fairlamb D, Gower N, et al: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC)—Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21:291,2002, (abstr 1161)

10.1136/bmj.311.7010.899

10.1200/JCO.1994.12.2.360

10.1634/theoncologist.6-suppl_1-8

10.1200/JCO.1998.16.7.2459

10.1200/JCO.1999.17.1.12

10.1200/JCO.2000.18.3.623

10.1200/JCO.1998.16.6.2133

10.1200/JCO.2000.18.1.122

10.1200/JCO.2000.18.6.1351

10.1200/JCO.2000.18.19.3390

10.1200/JCO.2001.19.13.3210

10.1016/S0169-5002(99)00067-7

10.1200/JCO.1999.17.11.3522

10.1002/cncr.10810

10.1054/bjoc.2000.1413

10.1111/j.1440-1843.1996.tb00010.x

10.1038/bjc.1996.634

10.1056/NEJMoa011954

10.2165/00019053-200220050-00004

10.1097/00001813-199907000-00013

10.1038/sj.bjc.6690426

10.1093/jnci/94.4.291

Ramsey SD: Incorporating economic analysis into clinical practice guidelines: A guide for users. ACP J Club 137:11,2002-13,

Lilenbaum RC, Herndon J, List M, et al: Single agent (SA) versus combination chemotherapy (CC) in avanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness. Proc Am Soc Clin Oncol 21:1,2002, (abstr 2)

Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLCSG). Proc Am Soc Clin Oncol 21:291a,2002, (abstr 1162)

10.1023/A:1012208711013

10.1016/S0140-6736(00)04644-4

10.1200/JCO.2002.12.112

10.1016/S0169-5002(00)00094-5

10.1093/jnci/92.13.1074

10.1023/A:1013582618920

10.1023/A:1013574413217

10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8

10.1093/jnci/94.3.173

10.1093/jnci/95.5.341

10.1093/jnci/91.1.66

10.1634/theoncologist.6-suppl_1-4

10.1200/JCO.2000.18.13.2529

10.1093/jnci/95.5.362

10.1200/jco.2002.20.5.1335

10.1200/JCO.2001.19.5.1336

10.1200/JCO.2000.18.12.2354

Miller V, Fossella F, DeVore R, et al: Docetaxel (D) benefits lung cancer symptoms and quality of life (QoL) in a randomized phase III study of non-small cell lung cancer (NSCLC) patients previously treated with platinum-based therapy. Proc Am Soc Clin Oncol 18:491,1999, (abstr 1895)

10.1200/JCO.2000.18.10.2095

Dancey J, Shepherd F, Ramlau R, et al: Quality of life (QOL) assessment in a randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18:491,1999, (abstr 1896)

10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F

10.1200/JCO.1999.17.7.2081

Sculier JP, Lafitte JJ, Berghmans T, et al: A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer: The European Lung Cancer Working Party. Lung Cancer 29:67,2000-73,

10.3109/07357909909021419

10.1200/JCO.1995.13.7.1609

Spiridonidis CH, Laufman LR, Carman L, et al: Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial. Ann Oncol 12:89,2001-94,

Kakolyris S, Papadakis E, Tsiafaki X, et al: Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer: A multicenter phase II: study. Lung Cancer 32 :179,2001-187,

Pectasides D, Kalofonos HP, Samantas E, et al: An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-operative Oncology Group. Anticancer Res 21:3005,2001-3010,

10.1002/1097-0142(20011101)92:9<2391::AID-CNCR1587>3.0.CO;2-M

10.1002/1097-0142(20011201)92:11<2902::AID-CNCR10103>3.0.CO;2-O

10.1016/S0959-8049(00)00419-6

10.1200/JCO.2003.10.038

Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD 1839 (Iressa) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxed-based regiment (IDEAL2). Proc Am Soc Clin Oncol 21:292a,2002, (abstr 1166)

10.1097/00000421-199308000-00005

10.1002/ssu.2980100106

10.2214/ajr.174.3.1740769

Higashi K, Ueda Y, Arisaka Y, et al: 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 43:39,2002-45,

10.1378/chest.119.2.333

10.1016/S0003-4975(99)00618-9

10.1038/sj.bjc.6690661

10.1200/JCO.2000.18.15.2798

Herbst RS, Yano S, Kuniyasu H, et al: Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clinical Cancer Res 6:790,2000-797,

Zhou X, Kemp BL, Khuri FR, et al: Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clinical Cancer Res 6:559,2000-565,

10.1002/(SICI)1096-9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X

Catzavelos C, Tsao MS, DeBoer G, et al: Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: A prognostic factor independent of Ras. Cancer Res 59:684,1999-688,

Marchetti A, Bertacca G, Buttitta F, et al: Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clinical Cancer Res 5:2077,1999-2081,

10.1016/S0140-6736(96)91203-9

10.1073/pnas.191502998

10.1073/pnas.241500798

10.1200/JCO.2002.06.037

10.1200/JCO.2002.04.178

10.1200/JCO.2000.18.6.1378

10.1200/JCO.1999.17.11.3676

10.1200/JCO.1996.14.9.2511

10.1200/JCO.1994.12.11.2471

Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. [erratum appears in J Clin Oncol 17:3860, 1999]. J Clin Oncol 17:2971,1999-2994,

10.1200/JCO.2002.07.177

Seidenfeld J, Piper M, Aronson N: Systematic review of controlled trials on erythropoietin to support evidence-based guidelines. Oncology (Huntington) 16:171,2002-188,

10.1016/S0140-6736(97)06305-8

10.1016/S0167-8140(99)00087-0

10.1200/JCO.1998.16.9.3082

10.1038/bjc.1998.678

10.1200/JCO.1998.16.11.3518

10.1002/(SICI)1097-0142(19980315)82:6<1037::AID-CNCR5>3.0.CO;2-B

10.1200/JCO.1996.14.4.1065

10.1016/S0360-3016(01)01482-1

10.1002/1097-0142(20010901)92:5<1213::AID-CNCR1440>3.0.CO;2-0

10.1634/theoncologist.6-suppl_1-20

10.1136/bmj.325.7362.465

10.1016/S0360-3016(02)02989-9

10.1016/S0936-6555(96)80041-0

10.1016/S1278-3218(00)88254-2

10.1016/S0936-6555(05)80446-7

10.1016/S0360-3016(00)00607-6

10.1016/0360-3016(90)90320-J

10.1016/S0169-5002(01)00242-2

10.1177/107327480100800405

10.1378/chest.118.5.1419

Ost D: Photodynamic therapy in lung cancer. Oncology (Huntington) 14:379,2000-386,

10.1034/j.1399-3003.1999.14d13.x

10.1016/S0169-5002(98)00020-8

10.1023/A:1008338312647

10.1016/S0360-3016(96)85008-5

10.3171/jns.2002.97.6.1276

10.1002/(SICI)1097-0142(19971201)80:11<2075::AID-CNCR6>3.0.CO;2-W

Hoffman R, Sneed PK, McDermott MW, et al: Radiosurgery for brain metastases from primary lung carcinoma. Cancer Journal 7:121,2001-131,

10.1067/mtc.2002.121678

10.1016/S0169-5002(02)00030-2

10.1016/S0360-3016(99)00507-6

10.1159/000056402

10.1002/ijc.1016

10.1067/mtc.2001.116201

10.1378/chest.119.5.1469

10.1016/S0003-4975(97)01284-8

10.1016/S0003-4975(96)00611-X

10.1097/00000421-200202000-00017

10.1007/s10434-001-0663-7

Yoshino I, Yohena T, Kitajima M, et al: Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 7:204,2001-209,

10.1016/S0003-4975(00)02509-1

10.1002/(SICI)1098-2388(199906)16:4<293::AID-SSU4>3.0.CO;2-E

10.1053/slas.2000.5600

10.1016/S0003-4975(00)01145-0

10.1016/0003-4975(95)00893-4

10.1378/chest.115.6.1494

10.1016/S0003-4975(00)01731-8

10.1016/S0169-5002(01)00332-4

10.1016/S0003-4975(01)03257-X

Bury T, Corhay JL, Duysinx B, et al: Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 14:1376,1999-1380,

10.1023/A:1008437915860

Hicks RJ, Kalff V, MacManus MP, et al: The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: Impact on management and prognostic stratification. J Nucl Med 42:1605,2001-1613,

10.1378/chest.120.6.1791

Johnson BE, Cortazar P, Chute JP: Second lung cancers in patients successfully treated for lung cancer. Semin Oncol 24:492,1997-499,

10.1093/jnci/90.18.1335

10.1056/NEJM200011303432208

10.1016/S0140-6736(99)06093-6

10.1002/1097-0142(20001201)89:11+<2474::AID-CNCR26>3.0.CO;2-2

10.1016/S0169-5002(01)00416-0

10.1016/S0140-6736(97)08229-9

10.1148/radiology.201.3.8939234

10.1148/radiology.213.3.r99dc38641

10.1378/chest.117.6.1568

10.1002/1097-0142(20011215)92:12<3051::AID-CNCR10106>3.0.CO;2-S

10.1378/chest.113.3.696

10.1016/S0169-5002(99)00058-6

10.1093/jnci/93.18.1385

10.1093/jnci/90.13.991

Scott FM, Modali R, Lehman TA, et al: High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clinical Cancer Res 3:479,1997-482,

Tockman MS, Mulshine JL, Piantadosi S, et al: Prospective detection of preclinical lung cancer: Results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clinical Cancer Res 3:2237,1997-2246,

Crowell RE, Gilliland FD, Temes RT, et al: Detection of trisomy 7 in nonmalignant bronchial epithelium from lung cancer patients and individuals at risk for lung cancer. Cancer Epidemiol Biomarkers Prev 5:631,1996-637,

10.1089/hyb.1998.17.339

10.1016/S0169-5002(97)00095-0

Esteller M, Sanchez-Cespedes M, Rosell R, et al: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. [erratum appears in Cancer Res 1999 Aug 1;59(15):3853]. Cancer Res 59:67,1999-70,

10.1097/00063198-200107000-00010

10.1289/ehp.99107s2289

10.1023/A:1012518223463

10.1097/00004032-200207000-00001

10.1038/sj.onc.1205798

10.1093/jnci/91.14.1194

Schuller HM: Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nature Reviews. Cancer 2:455,2002-463,

10.1038/sj.onc.1205802

10.1038/sj.onc.1205832

10.1038/sj.onc.1205803

10.1080/028418699432239

Eckhardt SG, Pulte DE, Hilsenbeck SG: Response to chemotherapy in smoking and non-smoking patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 14:357,1995, (astract)

10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H

10.1093/jnci/93.14.1081

10.1200/JCO.2002.10.085

10.1093/jnci/92.12.977

10.1093/jnci/93.8.605

10.1038/sj.bjc.6600370